Terminated OBSERVATIONAL NCT02436642

AVERT Plus Post-Market Registry

Sponsor: Osprey Medical, Inc

Updated 7 times since 2017 Last updated: May 18, 2016 Started: May 31, 2015 Primary completion: Jun 30, 2015 Completion: Jun 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

business decision

Other terminated trials from Osprey Medical, Inc

Radiographic Contrast Agent Nephropathy · Phase NA · Nov 2013

More terminations from Osprey Medical, Inc

Other Coronary Artery Disease trials with similar outcome

Browse all Coronary Artery Disease trials

This observational or N/A phase trial investigates Coronary Artery Disease and is currently terminated or withdrawn. Osprey Medical, Inc leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated
Sep 2024 — Sep 2025 [monthly]

Terminated
Jul 2024 — Sep 2024 [monthly]

Terminated
Jan 2021 — Jul 2024 [monthly]

Terminated
Jun 2018 — Jan 2021 [monthly]

Terminated

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Terminated

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Terminated NA

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Osprey Medical, Inc

Data source: Osprey Medical, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lübeck, Germany